Saptalis Pharma launches fluoxetine oral solution, USP 20 mg/5 mL for treatment of mental health conditions
Hauppauge-Headquartered Saptalis Pharmaceuticals, a rapidly growing company focused on the development, manufacturing, and commercialization of specialty pharmaceutical products, has announced the commercial launch of fluoxetine oral solution, USP 20 mg…